Clinical Trial Update: Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 study of Fordadistrogene Movaparvovec for early-stage Duchenne muscular dystrophy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Fordadistrogene Movaparvovec (fordadistrogene movaparvovec)

Snippet

Sponsor: Pfizer | Conditions: Muscular Dystrophy, Duchenne | Phase 2 | Status: TERMINATED